<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03936933</url>
  </required_header>
  <id_info>
    <org_study_id>EF 160</org_study_id>
    <nct_id>NCT03936933</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients With Breast Cancer</brief_title>
  <official_title>Two Arm, Multicentric, Randomized, Open Label, Parallel, Multiple Dose Study Subcutaneous Injection of Goserelin 3.6 mg (Eurofarma) vs ZOLADEX 3.6 mg (AstraZeneca) Administered Subcutaneously in Premenopausal Patients With Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurofarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurofarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two arm, multi centric, randomized, open label, parallel, multiple dose pharmacodynamic&#xD;
      study in premenopausal patients with advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase III, two arm, multi centric, randomized, open label, parallel, multiple dose&#xD;
      pharmacodynamic study in premenopausal patients with breast cancer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Goserelin acetate 3.6 mg Injection Eurofarma Laboratorios S.A Dose: 3.6 mg, Subcutaneously at every 28 days&#xD;
Reference product -R ZOLADEX® 3.6mg Injection. Dose: 3.6 mg, Subcutaneously at every 28 days</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate and compare the pharmacodynamics</measure>
    <time_frame>85 days</time_frame>
    <description>Percentage of patients with a mean estradiol concentration &lt;30 pg/mL at day 85 days (EOS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Goserelin acetate 3.6 mg Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.6 mg, Subcutaneously at every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZOLADEX® 3.6mg Injection.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3.6 mg, Subcutaneously at every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin acetate 3.6 mg Injection</intervention_name>
    <description>3.6 mg, Subcutaneously at every 28 days</description>
    <arm_group_label>Goserelin acetate 3.6 mg Injection</arm_group_label>
    <other_name>Goserelin acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZOLADEX® 3.6mg Injection</intervention_name>
    <description>3.6 mg, Subcutaneously at every 28 days</description>
    <arm_group_label>ZOLADEX® 3.6mg Injection.</arm_group_label>
    <other_name>Zoladex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pre-menopausal* female patients of 18 to 59 years of age (both inclusive)&#xD;
&#xD;
             * Premenopausal female is defined by one of the following criteria: menstruating&#xD;
             actively (&lt; 4 months since last menstrual period [LMP]) or between 4 and 12 months&#xD;
             after LMP with a premenopausal FSH level; patients younger than 59 years of age who&#xD;
             became amenorrheic while on adjuvant chemotherapy will be eligible only if the FSH&#xD;
             level is in the premenopausal range (&lt;22.3 IU/litre). [1]&#xD;
&#xD;
          2. BMI 18.5 to 30 kg/m2 (both inclusive).&#xD;
&#xD;
          3. Patient with a confirmed diagnosis of early or advanced breast cancer (TNM stage I,&#xD;
             II, III or stage IV or recurrent metastatic disease) who are scheduled to start&#xD;
             goserelin therapy as per Investigator discretion.&#xD;
&#xD;
          4. Hormone sensitivity (ER positive) of primary or secondary tumour tissue&#xD;
&#xD;
          5. Patients with baseline estradiol levels &gt;30 pg/mL&#xD;
&#xD;
          6. Patients must be able to understand the investigational nature of this study and to&#xD;
             give written informed consent prior to the participation in the trial.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.&#xD;
&#xD;
          8. Patients with life expectancy of at least 3 months as judged by the Investigator.&#xD;
&#xD;
          9. Patient should have recovered from any toxic effects of previous chemotherapy as&#xD;
             judged by the Investigator.&#xD;
&#xD;
         10. Patient should be able to comply with study requirement in the opinion of&#xD;
             Investigator.&#xD;
&#xD;
         11. Non-smoker defined as non-smoker for at least 6 months (i.e. subject has not smoked or&#xD;
             used any tobacco products for the 6 months prior to the screening visit).&#xD;
&#xD;
         12. Patients must not have taken any anti-androgens, estrogen, antiestrogen, aromatase&#xD;
             inhibitors or hormonal forms of contraception within past one month of screening.&#xD;
             Patient may have had recent use of oral contraceptive pills but these must be&#xD;
             discontinued 30 days prior to dosing.&#xD;
&#xD;
         13. Adequate hematologic status, renal and liver function.&#xD;
&#xD;
         14. Women of childbearing potential (WOCBP*) must not be pregnant or breastfeeding (as&#xD;
             documented by a negative serum pregnancy test at screening and negative urine&#xD;
             pregnancy test at baseline).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are not able to provide written informed consent.&#xD;
&#xD;
          2. Patients who are menopausal&#xD;
&#xD;
          3. Patients who are scheduled to receive any chemotherapy/radiotherapy in addition to&#xD;
             goserelin.&#xD;
&#xD;
          4. Patients who are already on GnRH receptor agonist or antagonist therapy.&#xD;
&#xD;
          5. Patients who have previously failed on GnRH receptor agonist or antagonist therapy for&#xD;
             breast cancer treatment..&#xD;
&#xD;
          6. Presence of life-threatening metastatic visceral disease, defined as extensive hepatic&#xD;
             involvement, or any degree (proven or suspected) of brain or leptomeningeal&#xD;
             involvement (past or present) or symptomatic pulmonary lymphangitic spread. Patients&#xD;
             with discrete pulmonary parenchymal metastases are eligible, provided their&#xD;
             respiratory function is not compromised as a result of the disease.&#xD;
&#xD;
          7. Patients who are intended to be started on any medication apart from study drug that&#xD;
             can have impact on any of the study endpoints.&#xD;
&#xD;
          8. Patients who are pregnant or breastfeeding.&#xD;
&#xD;
          9. Concurrent malignancy or history of malignancy (apart from disease condition under&#xD;
             study) within last 5 years before screening except curatively treated carcinoma in&#xD;
             situ of the uterine cervix or basal cell carcinoma of the skin&#xD;
&#xD;
         10. Patients with a clinically significant medical condition other than breast cancer&#xD;
             including but not limited to renal, hepatic, gastrointestinal, endocrine,&#xD;
             cardiovascular, neurological or psychiatric disease, alcohol or substance abuse, or&#xD;
             any other condition that may affect the patient's health or the outcome of the trial&#xD;
             as judged by the investigator.&#xD;
&#xD;
         11. Presence of clinically significant physical exam, laboratory, medical history, ECG&#xD;
             findings that in the opinion of the Investigator may interfere with trial conduct,&#xD;
             patient safety, or interpretation of results.&#xD;
&#xD;
         12. Patients with a known hypersensitivity to GnRH, GnRH-agonist analogues or any of the&#xD;
             components in IMP.&#xD;
&#xD;
         13. Patients receiving anticoagulation medications.&#xD;
&#xD;
         14. Patients with uncontrolled diabetes mellitus (HbA1c &gt; 8 % as per ADA) at randomization&#xD;
             (those who have controlled blood sugar (fasting) will be eligible for randomization)&#xD;
&#xD;
         15. Patients with confirmed signs or symptoms related to cerebral metastasis or&#xD;
             radiographically confirmed brain metastasis.&#xD;
&#xD;
         16. Uncontrolled hypertension (systolic blood pressure [BP] &gt;140 or diastolic BP &gt;90mm Hg)&#xD;
             or uncontrolled cardiac arrhythmias. (Patients with hypertension controlled by&#xD;
             antihypertensive therapies are eligible).&#xD;
&#xD;
         17. Patients with a QTc&gt;450ms on the ECG at screening.&#xD;
&#xD;
         18. History of clinically significant cardiovascular disorder&#xD;
&#xD;
         19. Use of any recreational drugs (cocaine, amphetamines, barbiturates, benzodiazepines,&#xD;
             cannabinoids and morphine) or history of drug or alcohol abuse within the past 1 year,&#xD;
             as judged by the Investigator, or a positive result on the urine drug/alcohol screen&#xD;
             which is not consistent with current medical treatment.&#xD;
&#xD;
         20. Concomitant use of medicinal products known to prolong the QT interval or medicinal&#xD;
             products able to induce Torsade de pointes such as class IA (e.g. quinidine,&#xD;
             disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide)&#xD;
             antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics.&#xD;
&#xD;
         21. A positive hepatitis screen including hepatitis B surface antigen or HCV antibodies.&#xD;
&#xD;
         22. Patients who test positive for HIV and/or syphilis.&#xD;
&#xD;
         23. The receipt of an investigational product, or participation in a drug research study&#xD;
             within a period of 30 days prior screening or 5 half-lives within the last dose of&#xD;
             investigational product, whichever is longer. Current use of any drugs that are known&#xD;
             to interfere with goserelin metabolism or to cause a drug-drug interaction.&#xD;
&#xD;
         24. Donation / loss of blood/plasma or blood product (without replenishment) (1 unit or&#xD;
             350 mL) within 180 days prior to receiving the first dose of study medicine.&#xD;
&#xD;
         25. Patients with a mental incapacity, unwillingness, or language barrier that precludes&#xD;
             the ability to understand or cooperate with study procedures.&#xD;
&#xD;
         26. Presence of clinically significant findings on the physical exam, laboratory testing,&#xD;
             medical history, ECG that in the opinion of the Investigator may interfere with trial&#xD;
             conduct, patient safety, or interpretation of results.&#xD;
&#xD;
         27. Any contraindications for goserelin administration.&#xD;
&#xD;
         28. Females of reproductive potential unwilling to use acceptable contraception (as&#xD;
             defined in the protocol) starting at least four weeks before the study drug&#xD;
             administration and up to 12 weeks after the after the last dose of study drug&#xD;
             administration.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cassiano Berto</last_name>
    <phone>+551150908600</phone>
    <phone_ext>8412</phone_ext>
    <email>cassiano.berto@eurofarma.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mahatma Gandhi Cancer Hospital &amp; Research Institute</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andhra Pradesh</state>
        <zip>530017</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Mr Reddy Boya, Doctor</last_name>
      <phone>0891-2878787</phone>
      <email>mgch.irb@gmail.co9m</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>It is not yet known if there will be a plan to make IPD available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

